Malamut Richard 4/A

What Happened

• Richard Malamut, a member of Pelthos Therapeutics' board of directors, received restricted stock unit (RSU) awards (transaction code A) on three dates: 6,450 RSUs on 2024-06-14, 19,108 RSUs on 2025-07-02, and 2,454 RSUs on 2025-11-13. The combined total reported in this amended filing is 28,012 RSUs (amounts adjusted for a 1-for-10 reverse split).
• Each award is reported at $0.00 per share (typical for RSU grants, which are compensation rather than cash purchases). These RSUs represent the right to receive one share of Pelthos common stock upon vesting.

Key Details

• Transaction dates and prices:
  • 2024-06-14 — 6,450 RSUs @ $0.00 (acquired)
  • 2025-07-02 — 19,108 RSUs @ $0.00 (acquired)
  • 2025-11-13 — 2,454 RSUs @ $0.00 (acquired)
• Total reported in this amendment: 28,012 RSUs (post 1-for-10 reverse split adjustment).
• Shares owned after transaction: Not specified in the amended Form 4.
• Vesting / other footnotes:
  • F2: RSUs were granted as director compensation under the 2023 Equity Incentive Plan and vest in equal quarterly installments over three years, subject to continued service.
  • F1: This filing is an amendment moving previously reported RSU information into Table I (correcting earlier Form 4s filed between June 18, 2024 and July 7, 2025).
  • F3: Reported amounts reflect a 1-for-10 reverse stock split effected July 1, 2025.
• Filing timeliness: This is an amended Form 4 filed April 1, 2026 to correct prior reports; the amendment indicates prior reporting changes but does not itself explain any penalties or compliance status.

Context

• RSU grants are compensation awards, not open‑market purchases or sales; they only convert into shares as they vest, so they do not directly indicate an immediate buy/sell decision by the insider.
• The $0.00 grant price is standard for RSUs (no cash paid at grant); any future taxable event will generally occur as units vest and are settled into shares.